Format

Send to

Choose Destination
Drug Discov Today. 2015 Apr;20(4):393-8. doi: 10.1016/j.drudis.2014.09.003. Epub 2014 Sep 16.

An overview of FDA-approved biologics medicines.

Author information

1
Washington University in St Louis, St Louis, MO 63110, USA. Electronic address: michael.kinch@wustl.edu.

Abstract

Recombinant DNA technologies revolutionized medicine. Herein, the approvals and mechanistic basis of biologics-based medicines are analyzed. The overall and relative rate of FDA approvals for recombinant proteins grew from the 1980s through the first half-decade of the new millennium. Over time, the number of biologics gaining approval for an orphan indication has climbed to more than 50% in the current decade. The field has been dynamic in terms of the types of biologics, indications targeted and the mechanistic basis of drug activity. Despite impressive increases in recombinant-protein-based medicine, the rate of new biologics approvals could have leveled out.

PMID:
25220442
DOI:
10.1016/j.drudis.2014.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center